Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Helsinn Therapeutics (U.S.), Inc., Novartis Pharmaceuticals Corporation, and Taiho Oncology.

Community Practice Connections™: 1st Annual School of Nursing Oncology™

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based


Activity Overview

The 1st Annual School of Nursing Oncology™ was developed to provide the latest information on key topics in oncology that can readily be applied to nursing clinical practice in a variety of settings. This enduring activity features faculty video commentary on key topics presented at the live meeting, including strategies to help optimize patient management and insights into the evolving treatment landscape for a variety of commonly encountered malignancies. This activity will also address such topics as landmark and recent key trials in oncology and the clinical implications of their results.

Key areas of focus include:

  • Overview and updates in immunotherapy in melanoma
  • Treatment considerations for patients with non–small cell lung cancer
  • Management of treatment-related adverse events, including chemotherapy-induced nausea and vomiting
  • Advancements in gastrointestinal and genitourinary cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Helsinn Therapeutics (U.S.), Inc., Novartis Pharmaceuticals Corporation, and Taiho Oncology.

CME/CE Activity Table of Contents

  • Overview and Updates in Advanced Melanoma and Immunotherapy
    Video commentary featuring Grace Cherry, RN, MSN, NP
  • Non–Small Cell Lung Cancer: Treatment Considerations and Management Strategies
    Video commentary featuring Beth Eaby-Sandy, CRNP, OCN
  • Advancements in the Management of Gastrointestinal and Genitourinary Cancers
    Video commentary featuring Laura Wood, RN, MSN, OCN

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational program is directed toward nurses interested in the management of patients with cancer. Other healthcare professionals interested in the management of patients with cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Identify recent advancements in the management of different malignancies
  • Describe the role of tumor testing options in guiding treatment selection for patients with different malignancies
  • Recognize disease-related and treatment-related adverse events for different malignancies
  • Appraise clinical evidence pertaining to the management of conditions commonly encountered in the oncology clinical setting
  • Develop evidence-based supportive care strategies for patients with different malignancies
  • Outline effective multidisciplinary communication strategies to help optimize patient outcomes

Faculty, Staff, and Planners' Disclosures



Grace Cherry, RN, MSN, NP
Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, CA

Disclosure: Speakers Bureau: Genentech, Merck, Novartis

Laura S. Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Disclosure: Consultant/Advisory Boards: Exelixis; Speakers Bureau: Bristol-Myers Squibb, Novartis, Pfizer

Beth Eaby-Sandy, MSN, CRNP, OCN
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosure: Consultant/Advisory Boards: Abbvie, Takeda; Speakers Bureau: Bristol-Myers Squibb, Novartis, Pfizer

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

1 of 3
PER Pulse™ Recap

Overview and Updates in Advanced Melanoma and Immunotherapy

The incidence of skin cancer in the United States continues to climb, and melanoma accounts for most skin cancer-related mortality. Although melanoma lesions are often caught early and can be surgically excised, the treatment of advanced melanoma has historically been a significant clinical challenge.1 As our understanding of the role of abnormal cell signaling pathways and specific genetic mutations in the pathogenesis of melanoma has evolved, new treatments such as those that enhance the immune response and those that inhibit cellular proliferation have emerged.2 Nurses play a pivotal role in educating their patients regarding treatment therapies, as well as addressing potential side effects and setting treatment expectations.

Anti–CTLA-4 antibodies and anti–PD-1 antibodies have been studied extensively in the treatment of melanoma.3-5 New combinations have also been studied, and immune-related adverse events must be taken into consideration when selecting systemic therapy for patients with advanced melanoma. BRAF and MEK inhibitors have gained approval for the treatment of patients with advanced melanoma with certain BRAF mutations.5-8

Other agents have been studied for intralesional therapy for melanoma. Two of the more commonly used intralesional agents are talimogene laherparepvec, which uses a modified herpes simplex virus to attack tumors and deliver granulocyte-macrophage colony-stimulating factor (GM-CSF) to injected lesions, and interleukin-2, which has been studied extensively.9 Although new treatment options such as immunotherapy and targeted therapy have improved outcomes for patients with metastatic melanoma, treatment of patients with this disease remains an active area of clinical investigation. Nurses involved in the care of patients with melanoma must continue to remain aware of new treatment options that may offer improved efficacy and less toxicity. In this segment, Grace Cherry discusses recent advancements in the treatment of advanced melanoma and considerations for supportive care for different treatment options.


  1. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534. doi: 10.1200/JCO.2007.12.7837.
  2. Vennepureddy A, Thumallapally N, Motilal Nehru V, et al. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016;8(2):63-75. doi: 10.14740/jocmr2424w.
  3. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489. doi: 10.1038/nature10673.
  4. Robert C, Schacter J, Long GY, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532. doi: 10.1066/NEJMoa1503093.
  5. Larkin J, Chiarion Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. doi: 10.1056/NEJMoa1504030.
  6. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888. doi: 10.1056/NEJMoa1406037.
  7. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876. doi: 10.1056/NEJMoa1408868.
  8. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 1. 2017.

2 of 3
PER Pulse™ Recap

Non-Small-Cell Lung Cancer: Treatment Considerations and Management Strategies

As treatment options for patients with non-small-cell lung cancer (NSCLC) are becoming more personalized with the advent of targeted therapies, oncology nurses play a key role in the timely identification and management of adverse events (AEs) associated with these therapies, as well as other treatment modalities such as chemotherapy. Timely interventions may improve patient outcomes and facilitate adherence to treatment protocols.

Several targeted therapy options have been approved for patients with NSCLC. Patients with NSCLC who have EGFR mutations may have greater sensitivity to treatment with tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.1 Osimertinib is recommended as a second and later line of therapy for patients who have the EGFR T790M mutation who have progressed on earlier TKI therapy.1 Several toxicities have been reported with EGFR inhibitors, and the most common of these is rash.2 Multinational Association of Supportive Care in Cancer recommendations for the treatment of rash associated with EGFR inhibitors include topical alclometasone, fluocinonide, or clindamycin. Systemic options include doxycycline, minocycline, and isotretinoin.3 Diarrhea is also not uncommon with the use of EGFR inhibitors. Other toxicities associated with EGFR inhibitors include interstitial lung disease/pneumonitis, cardiomyopathy, and transaminitis.

ALK inhibitors such as alectinib, brigatinib, ceritinib, and crizotinib have also been approved for the treatment of patients with NSCLC, and carry their own toxicity profiles. Common toxicities associated with the use of crizotinib include visual changes, including difficulty with light and dark accommodation. Other common toxicities, include vomiting, diarrhea, and edema. Ceritinib carries significant challenges with gastrointestinal-related AEs, including diarrhea, nausea, and vomiting.4 Fatigue is also commonly seen with ceritinib use.4 In clinical trials, brigatinib was shown to have a relatively high incidence of interstitial lung disease early in the treatment course; treatment is initiated with a 7-day period of 90 mg daily, followed by 180 mg daily. BRAF/MEK inhibitor combinations have been associated with pyrexia.

One of the most worrisome toxicities for patients is the emergence of chemotherapy-induced nausea and vomiting (CINV). According to recent National Comprehensive Cancer Network guidelines, carboplatin AUC ≥4, any regimen with an anthracycline and cyclophosphamide, and cisplatin have all been classified as highly emetogenic chemotherapy.5 Regimens with carboplatin AUC less than 4 are moderately emetogenic.

Serotonin receptor antagonists and neurokinin-1 receptor antagonists are key classes of antiemetic therapy used in the treatment of CINV. Other classes of therapy include corticosteroids, benzodiazepines, dopamine receptor antagonists, and cannabinoids. Newer agents include the combination of a neurokinin 1 receptor antagonist (netupitant) and a serotonin receptor antagonist (palonosetron). The combination of these two medicines and dexamethasone has been studied extensively and shown improvement in complete response to CINV compared with the combination of palonosetron and dexamethasone.6 Another newer agent that has emerged is a long-acting formulation of granisetron, used in the prevention of acute and delayed CINV. Olanzapine has historically been used as an atypical antipsychotic, but recent studies have established its efficacy in the treatment of CINV.6

Utilization of clear written instructions on how to take prophylactic and as needed antiemetics can be beneficial, as well as maintaining a record of CINV between office visits. Patient navigation, home telehealth, and nurse care management are commonly used, and care coordination increases the odds of appropriate health care use.7 In this segment, Beth Eaby-Sandy discusses management of side effects associated with cancer treatments, including chemotherapy and targeted therapies for NSCLC.


  1. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 8. 2017.
  2. Lacouture ME. Mechanisms of cutaneous toxcities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803-812.
  3. Lacouture ME. Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079-1095. doi: 10.1007/s00520-011-1197-6.
  4. Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):135701367. doi: 10.1016/j.jtho.2017.07.005.
  5. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2. 2017.
  6. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26(6):1081-1090. doi: 10.1093/annonc/mdv138.
  7. Gorin SS, Haggstrom D, Han PKJ, et al. Cancer care coordination: a systematic review and meta-analysis of over 30 years of empirical studies [published online July 6, 2017]. Ann Behav Med. doi: 10.1007/s12160-017-9876-2.

3 of 3
PER Pulse™ Recap

Advancements in the Management of Gastrointestinal and Genitourinary Cancers

Gastrointestinal Cancers
Several new treatment choices have emerged for patients with metastatic colorectal cancer (mCRC), with the approval of capecitabine, oxaliplatin, irinotecan, anti-EGFR monoclonal antibodies, anti-VEGF agents, regorafenib, and trifluridine/tipiracil. Clinical studies have confirmed the efficacy of these treatment options, as well as contributed to the identification of potential adverse events that must be addressed in a timely fashion.1-4

New treatment strategies and therapeutic options continue to emerge at a rapid pace. For patients with RAS wild-type cancer with left-sided tumors, EGFR antibodies may be a viable option.3 Patients who are symptomatic and need response may derive benefit from reinduction or rechallenge with oxaliplatin.1 Options such as tifluridine/tipiracil have expanded treatment options, even in those with reduced performance status. Sequential treatment with regorafenib and trifluridine/tipiracil may also be appropriate for patients with good performance status.

Genitourinary Cancers
The treatment paradigm for different genitourinary cancers also continue to evolve at a rapid pace, with new treatment options and clinical evidence presenting the potential to improve outcomes for patients with prostate, renal, and urothelial/bladder cancers. To begin with, patients with metastatic prostate cancer have been the subject of several recent studies that have addressed the addition of docetaxel or abiraterone to androgen deprivation therapy, such as CHAARTED, LATITUDE, and STAMPEDE.5-7 These studies have shown an overall survival benefit relative to androgen-deprivation therapy alone. 

For patients with renal cancer, there has been a great expansion of treatment options over the past decade, with the incorporation of agents targeting VEGF (axitinib, bevacizumab, pazopanib, and sunitinib), as well as agents targeting the mammalian target of rapamycin pathway (everolimus, temsirolimus).8 The phase III METEOR study compared cabozantinib with everolimus in the treatment of patients with advanced renal cell carcinoma (RCC) who had disease progression on prior VEGFR-TKI therapy. This study found that patients treated with cabozantinib had a significantly higher response rate (17% versus 3%; P<.0001), greater progression-free survival (7.4 versus 3.9 months; P = .00026), and overall survival (21.4 months versus 16.5 months; P<.0001).9 The phase II CABOSUN study compared cabozantinib versus sunitinib in the treatment of patients with advanced RCC, including patients with IMDC intermediate or poor risk. This study showed significant clinical improvement in progression free survival and objective response rate in the group treated with cabozantinib compared with patients who received sunitinib.10

Immunotherapy with checkpoint inhibitors has significantly changed the treatment paradigm for patients with bladder cancer. Monoclonal antibodies targeting PD-1 such as nivolumab and pembrolizumab, as well as its ligand PD-L1 (atezolizumab, avelumab, and druvalumab) have all been approved for patients with metastatic bladder cancer. In this segment, Laura Wood discusses recent advancements in the treatment of genitourinary malignancies.


  1. Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic colorectal cancer – beyond first and second line combination therapies. Cancer Treat Rev. 2017;59:54-60. doi: 10.1016/j.ctrv.2017.04.007.
  2. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-1919. doi: 10.1056/NEJMoa1414325.
  3. Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34(2):179-185. doi: 10.1200/JCO.2015.63.9674.
  4. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9683):303-312. doi: 10. 1016/S0140-6736(12)61900-X.
  5. Sweeney CJ, Chen Y, Liu, G, et al. 720PD - Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Poster presented at  ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 720PD. Accessed September 16, 2017.
  6. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338-351. doi: 10.1056/NEJMoa1702900.
  7. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. doi: 10.1056/NEJMoa1704174.
  8. Rodriguez-Vida A, Hutson TE, Bellmunt J, Strojbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2(2):e000185. doi: 10.1136/esmoopen-2017-000185.
  9. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3.
  10. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591-597. doi: 10.1200/JCO.2016.70.7398.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By